RSS-Feed abonnieren
DOI: 10.1055/s-2008-1039258
© Georg Thieme Verlag KG Stuttgart · New York
Correlation of Transplant Vasculopathy with Long-Term Survival
Publikationsverlauf
Publikationsdatum:
30. April 2009 (online)

Introduction
Survival after heart transplantation (HTx) has improved, largely due to improvements in early survival. The current half-life time after HTx is now about 10 years [1], [2], [3]. In agreement with data from the ISHLT registry but in contrast to data from Oeynhausen [3], the DHZB experience demonstrates significantly improved survival in patients transplanted between 1992 and 2001 [2]. In contrast to registry data, survival after HTx after 2001 at the DHZB is not improved in comparison with the preceding period ([Fig. 1]).
Fig. 1 Survival after HTx at DHZB conditional on 1-month survival stratified with respect to time period of HTx.
Fig. 2 Survival conditional on 5-year survival, no children, HTx later than 1991.
References
- 1
Roussel J C, Baron O, Perigaud C, Bizouarn P, Pattier S, Habash O. et al .
Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity,
and risk factors for mortality.
J Heart Lung Transplant.
2008;
27
486-493
MissingFormLabel
- 2
Taylor D O, Edwards L B, Boucek M M, Trulock E P, Aurora P, Christie J. et al .
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth
official adult heart transplant report – 2007.
J Heart Lung Transplant.
2007;
26
769-781
MissingFormLabel
- 3
Tjang Y S, van der Heijden G J, Tenderich G, Grobbee D E, Korfer R.
Survival analysis in heart transplantation: results from an analysis of 1290 cases
in a single center.
Eur J Cardiothorac Surg.
2008;
33
856-861
MissingFormLabel
- 4
Wellnhofer E, Hiemann N E, Hug J, Dreysse S, Knosalla C, Graf K. et al .
A decade of percutaneous coronary interventions in cardiac transplant recipients:
a monocentric study in 160 patients.
J Heart Lung Transplant.
2008;
27
17-25
MissingFormLabel
- 5
Eisen H J, Tuzcu E M, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler H A. et al .
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant
recipients.
N Engl J Med.
2003;
349
847-858
MissingFormLabel
- 6
Kobashigawa J A.
Statins and cardiac allograft vasculopathy after heart transplantation.
Semin Vasc Med.
2004;
4
401-406
MissingFormLabel
- 7
Kobashigawa J A, Tobis J M, Mentzer R M, Valantine H A, Bourge R C, Mehra M R. et al .
Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after
heart transplant: reanalysis of the multicenter trial.
Am J Transplant.
2006;
6 (5 Pt 1)
993-997
MissingFormLabel
Dr. med. Ernst Wellnhofer
DHZB
Augustenburger Platz 1
13353 Berlin
Germany
Telefon: + 49 (0) 30 45 93 24 98
Fax: + 49 (0) 30 45 93 25 00
eMail: wellnhofer@dhzb.de